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Carborane confined nanoparticles based on the core cross-linked and boron-containing 
micelles (CL micelles) were prepared using the radical polymerization of poly(ethylene 
glycol)-block-poly(lactide) copolymer (PEG-b-PLA), which contained an acetal group at the 
PEG end and a methacryloyl group at the PLA end (acetal-PEG-b-PLA-MA), with 
polymerizable carborane (VB-carborane) as a cross-linker. No leakage of VB-carborane from 
the CL micelles was observed in PBS even in the presence of 10 % fetal bovine serum (FBS) 
at 37 ºC, whereas significant leakage (80 %) of VB-carborane was observed for the 
non-cross-linked (NCL) micelles under the same conditions. To clarify the biodistribution of 
both types of micelles, 125I (RI: radioisotope)-labeled CL and NCL micelles were injected into 
tumor-bearing BALB/c mice via the tail vein. The 125I-labeled CL micelles showed a 
remarkably prolonged blood circulation time (7.9 %ID/g) and high tumor accumulation 
(2.9 %ID/g) compared with the 125I-labeled NCL micelles (blood: 3.1 %ID/g, tumor: 
1.8 %ID/g) at 24 h after injection. Moreover, the biodistribution of the VB-carborane (boron 
species) was also evaluated using ICP-MS at 24 h after intravenous injection of the CL and 
NCL micelles. The boron concentrations in blood and tumor after injection of the CL micelles 
(blood: 13.5 %ID/g, tumor: 5.4 %ID/g) were also significantly higher than the concentrations 
after the injection of the NCL micelles (blood: 1.8 %ID/g, tumor: 1.4 %ID/g). Note that the 
biodistribution of the boron species in the CL micelles was similar to that of the 125I-labeled 
CL micelles, whereas the boron concentrations (%ID/g) in blood and tumor after injection of 
the NCL micelles were lower than those expected with the 125I concentrations (%ID/g) in 
blood and tumor. Thus, the boron concentration ratios of the CL micelles to the NCL micelles 
(CLICP/NCLICP) in blood (15.8) and tumor (3.8) were much higher than the 125I concentration 
ratios of CLRI/NCLRI in blood (2.5) and tumor (1.6). These differences might be caused by the 
suppression of the leakage of the VB-carborane from the CL micelles in the blood stream due 
to the existence of the cross-linking bonds between the VB-carborane and the PLA core. 
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Based on these results, the CL micelles composed of PEG-b-PLA copolymer cross-linked by 
carborane represent a promising approach to the creation of a novel boron carrier for boron 
neutron capture therapy (BNCT).  
 
1. Introduction 
 
Boron neutron capture therapy (BNCT) has attracted much attention as a selective and 
noninvasive cancer therapy using boron-10 (10B) compounds, which efficiently generate 
cytotoxic α-particles and 7Li nuclei within the cell diameter (5-9 µm) through the nuclear 
reaction of the 10B atom with low-energy thermal neutrons.[1],[2] Two types of the 
10B-compounds, sodium borocaptate (BSH) and L-4-dihydroxyboronylphenylalanine (BPA), 
have been approved for clinical trials so far. Due to the rapid clearance of these compounds 
from the blood stream (blood circulation time of BSH: t1/2 < 1 h)[3] a high dose of the 
10B-compound is generally required to allow a sufficient concentration of the 10B-compound 
to accumulate in the tumor tissue (20-30 µg of 10B atoms per gram of tumor tissue). 
Additionally, the non-specific distribution of these compounds also reduces the efficiency of 
their accumulation in the tumor tissue. To improve the effect of BNCT, the effective 
accumulation of boron compounds in the area of the tumor tissue is one of the key issues. 
A promising strategy in this regard is the concept of drug delivery systems (DDS). 
Matsumura and Maeda et al. have reported that a DDS based on nanomaterials, including 
proteins, drug-conjugated polymers and nano-sized particles, enabled the accumulation of 
drug in the tumor tissue due to the so-called “enhanced permeability and retention” (EPR) 
effect.[4],[5] Indeed, PEG-modified liposomes have been reported to be effective nano-sized 
carriers of hydrophilic and negatively charged BSH, thus enhancing biocompatibility, blood 
circulation time and accumulation in the tumor tissue. Although the PEG-modified liposomes 
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encapsulating the BSH showed higher accumulation in the tumor tissues compared to the free 
BSH due to the EPR effect,[6]-[8] the therapeutic efficacy of the PEG-modified liposomes 
encapsulating the BSH is still controversial due to the leakage of the encapsulated BSH from 
the liposome into the blood stream caused by the high ion osmotic pressure of the 
BSH-loaded interior of the liposome.[9] An alternative approach is the 
10B-compound-conjugated liposomes fabricated by covalently linking a lipid (hydrophobic 
group) with a 10B-compound (hydrophilic group) to suppress the leakage of the 
10B-compound into the blood stream.[10]-[12] The 10B-compound-conjugated liposome 
constructed from nido-carborane afforded a sufficiently high 10B concentration in the tumor 
tissue, without leakage of the 10B compound into the blood stream. However, the synthesis of 
nido-carborane required complicated preparation steps. Additionally, serious acute toxicity 
was observed in vivo because of the cytotoxicity of nido-carborane.[11] Thus, the development 
of a 10B-compound confined delivery system, which does not allow leakage of the 
10B-compound and is not toxic is a promising approach to cancer BNCT.  
Recently, a new class of drug delivery system has emerged, based on nano-sized polymeric 
micelles composed of PEG-block-poly(D,L-lactide) (PLA) copolymers (PEG-b-PLA) because 
the PEG-b-PLA micelles showed high biocompatibility, nontoxicity, long blood circulation 
time and high biodegradability.[13]-[16] The hydrophobic PLA core is able to accommodate 
hydrophobic drugs, and the brush-like hydrophilic PEG shell prevents protein adsorption and 
subsequent non-specific uptake by the reticuloendothelial system (RES) after intravenous 
injection. However, Chen et al. reported that hydrophobic fluorescent compounds 
incorporated into the core of the PEG-b-PLA micelle showed a loss of micelle integrity within 
the blood stream due to the interaction between the micelles and some blood components, 
leading to the rapid leakage of the hydrophobic fluorescent compounds within 15 min after 
intravenous injection.[17] To solve this problem, many studies have focused on the 
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stabilization of micelles, introducing chemical linkages into either the shell or the core 
segment to avoid the loss of micelle integrity.[18]-[20] We have also previously reported the 
preparation of core-polymerized PEG-b-PLA micelles possessing a methacryloyl group at the 
PLA chain end. Through the radical polymerization,[21],[22] the core-polymerized micelles 
eventually showed high dispersibility even after lyophilization as well as high stability against 
dilution, temperature changes and sodium dodecyl sulfate solution. Indeed, these 
above-mentioned approaches (polymerized or cross-linked micelles) are critical to the 
formulation of micelles that are resistant to the loss of micelle integrity. However, even 
though the polymerized or cross-linked micelles are employed, the leakage of the drug from 
the polymerized or cross-linked micelles is not completely suppressed due to the diffusion of 
the drug from the core to the blood stream when the drug is physically entrapped inside the 
core by hydrophobic interactions.[23],[24] 
In this study, we designed and prepared a core cross-linked and boron-containing micelles 
(CL micelles) using the radical copolymerization of PEG-b-PLA, which contains an acetal 
group at the PEG end and a methacryloyl group at the PLA end (acetal-PEG-b-PLA-MA), 
with hydrophobic 1,2-bis(4-vinylbenzyl)-closo-carborane (model for 10B-compound) as a 
cross-linker (Fig. 1). Note that the CL micelles suppress the leakage of carborane and the loss 
of micelle integrity in the blood stream, leading to a prolonged blood circulation time and 
enhanced accumulation in tumor tissues. The cross-linked core of the micelle is anticipated to 
gradually collapse through the biodegradation of the PLA segment after the therapy. 
Moreover, an acetal group at the tethered PEG chain end can be easily converted to an 
aldehyde group by hydrolysis with acid. The aldehyde group is known to easily react with 
hydrazide compounds, facilitating the installation of tumor-specific ligand molecules and 
radioactive tags for monitoring the biodistribution. We believe that the use of the CL micelles 
composed of acetal-PEG-b-PLA-MA and 1,2-bis(4-vinylbenzyl)-closo-carborane represents a 
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promising strategy for the fabrication of drug delivery systems, which deploy a sufficient 
quantity of 10B to tumor tissues. 
 
2. Experimental Section  
 
2.1. Materials and methods 
 
Azobisisobutyronitrile (AIBN; Wako Pure Chemical Industries, Ltd., Osaka, Japan) was 
purified by recrystallization from methanol and dried in vacuo. N,N-Dimethylacetamide 
(DMAc; Kanto Chemicals Co., Ltd., Tokyo, Japan), L-tyrosine hydrazide (Tokyo Chemical 
Industry Co., Ltd., Tokyo, Japan), sodium cyanoborohydride (Aldrich Chemical Co., Ltd., 
Milwaukee, WI, USA), p-toluenesulfonchloramide sodium salt (chloramine T; Kanto 
Chemicals Co., Ltd.) and sodium peroxodisulfate (Kanto Chemicals Co. Ltd.) were used as 
received. Water was purified using the Milli-Q system (Millipore). Dynamic light scattering 
measurements were conducted in phosphate buffered saline (PBS) at 37 °C using a Zetasizer 
Nano-ZS instrument (Malvern, UK) equipped with a 4.0 mW He–Ne laser (633 nm). Zeta 
potential measurement of the micelles was performed at 37 ºC in 5 mM phosphate buffer 
solution at pH 7.4 using a Zetasizer Nano ZS. 1H-NMR spectra were obtained in chloroform-d 
at 25 ºC with a JEOL EX270 spectrometer (JEOL, Japan). Chemical shifts were reported in 
ppm relative to CDCl3 (δ 7.26 ppm). Fluorescence spectra were recorded on an F-7000 
spectrometer (Hitachi, Japan). The concentration of boron atoms was determined with 
ICP-AES using an ICAP-575 emission spectrometer (Nippon Jarrell-Ash, Japan) and ICP-MS 
using an ELAN DRC II (PerkinElmer, Inc., USA). 1,2-Bis(4-vinylbenzyl)-closo-carborane 
(VB-carborane) was synthesized according to a previous study,[25] and the detailed procedure 
is described in the supporting information section. Acetal-PEG-b-PLA-MA was synthesized 
    
 - 7 - 
according to our previous study,[21] and the molecular weight of the PEG segment and the 
PLA segment of the block copolymer were estimated to be 9,500 and 5,000 g/mol. The block 
copolymer with the above-stated molecular weight was reported to form spherical micelles in 
aqueous solution[34] and to be stable in the presence of serum proteins.[24] 
Acetal-PEG-b-PLA-MA micelles were also prepared according to our previous study.[21] The 
average diameter and size distribution (= µ2/Γ2) of the acetal-PEG-b-PLA-MA micelles were 
found to be 45.8 nm and 0.135, respectively, as determined using DLS measurement. The 
cytotoxicity of NCL micelles, CL micelles, free VB-carborane, BPA and BSH were evaluated 
using the WST-8 assay, which is described in detail in the supporting information section (see 
supporting information, Fig. S4). 
 
All animal experiments were conducted humanely after approval from the Institutional 
Animal Experiment Committee of the University of Tsukuba and complied with the 
Regulations for Animal Experiments at our university and the Fundamental Guidelines for 
Proper Conduct of Animal Experiments and Related Activity in Academic Research 
Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and 
Technology. 
 
2.2. Preparation of the NCL and CL micelles 
 
A solution of VB-carborane (45 mg) and AIBN (1.5 mg) in chloroform (3.0 mL) was added 
dropwise to 100 mL of a stirred acetal-PEG-b-PLA-MA micelles solution in water (1.0 mg/L) 
to form oil in water (o/w) emulsion. After the o/w emulsion was maintained for 1 h and the 
solution was exposed to air at 25 °C for 3 h to evaporate the chloroform, the resulting micelle 
solution was purged with nitrogen gas for 20 min to completely remove the remaining 
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chloroform and dissolved oxygen. To prepare the cross-linked micelles (CL micelles), 
polymerization was conducted at 60 °C for 24 h. Purification was performed using repeated 
ultrafiltrations using a membrane with a molecular weight cut-off of 100,000 (VIVASPIN 4, 
Sartorius Stedim Biotech, Germany). For controls, non-cross-linked micelles (NCL micelles) 
encapsulating VB-carborane were prepared using the same procedure as that for CL micelles, 
except for the addition of AIBN and heating. To determine the average size and size 
distribution of the micelles, DLS measurement was performed in PBS at 37 °C. To confirm 
the encapsulation of VB-carborane into the micelles, the gel filtration chromatography was 
conducted on a PD-10 column (GE Healthcare, USA) using PBS as the eluent, and the boron 
atom concentration and light scattering intensity of each collected fraction were measured 
using ICP-AES and DLS, respectively. The loading content and efficiency of the boron atoms 
in the micelles were determined using ICP-AES according to a previous paper.[26] To 
determine whether the VB-carborane was covalently cross-linked in the core of the micelles, 
1H-NMR analysis of the lyophilized NCL and CL micelles was conducted in CDCl3 at 25 ºC. 
 
2.3. Leakage of VB-carborane from the NCL and CL micelles 
 
The NCL or CL micelle solution (1.0 mg/mL, 10 mL), with or without 10 % FBS, was 
poured into dialysis bags (MWCO: 100,000), and each bag was immersed in 90 mL of PBS 
with or without 10 % FBS at 37 °C. At a definite time interval, 0.5 mL of the solution inside 
the dialysis bag was sampled, and a fluorescence measurement was performed to determine 
the amount of VB-carborane that remained in each micelle based on the fluorescence intensity 
of the VB-carborane (λex: 339 nm, λem: 380 nm). 
 
2.4. Stability of the micelles against serum protein 
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The NCL or CL micelle solution (1.0 mg/mL, 90 µL) was added to 10 µL of FBS, followed 
by incubation at 37 ºC for 24 h. After a ten-fold dilution of the sample solutions and filtration 
through a 0.45 µm filter, 50 µL aliquots were subjected to SEC analysis using a JASCO 
HPLC system (JASCO, Tokyo, Japan) equipped with a refractive index (RI) detector 
(RI-2031), a fluorescence detector (FP-2020), and a Superose 6 10/30 GL column (GE 
Healthcare, USA) with 10 mM phosphate buffer (pH 7.4) at a flow rate of 0.50 mL/min at 
40 °C. 
 
2.5. Conjugation of tyrosine residues with NCL and CL micelles 
 
To clarify the biodistribution of the micelles, the preparation of 125I (RI: 
radioisotope)-labeled NCL and CL micelles were performed. Consistent with previous 
papers,[16],[30] a tyrosine residue (Tyr), as a site of radiolabeling, was introduced onto the NCL 
or CL micelles. An aqueous solution of NCL or CL micelles bearing acetal groups (10.0 mL, 
2.0 mg/mL) was adjusted to pH 2 using 1.0 M hydrochloric acid, and the resulting solution 
was stirred for 2 h at room temperature to prepare NCL or CL micelles with aldehyde groups. 
Purification was performed with dialysis against a large quantity of water (2.0 L) using a 
pre-swollen semi-permeable membrane (MWCO. 12,000–14,000) for 24 h. The dialysate 
water was exchanged at 2, 5 and 8 h after the beginning of dialysis. After the purification, 3.0 
mL of the solution was freeze-dried to determine the concentration and the degree of the 
functionality of the aldehyde group in the 1H-NMR spectra. As a typical example, the 
1H-NMR spectra of both the NCL and the CL micelles in CDCl3 showed a new signal at 9.8 
ppm, which can be attributed to the aldehyde group, along with the disappearance of the 
acetal signal at 4.8 ppm (see supporting information, Fig. S5), indicating that more than 90 % 
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of the acetal groups of both the NCL and the CL micelles can be converted to aldehyde 
groups. To a solution of the NCL or CL micelles bearing aldehyde groups (10.0 mL, 1.3 
mg/mL, [aldehyde] = ca. 90 µM) in 10 mM phosphate buffer (pH = 6.5), L-tyrosine (Tyr) 
hydrazide (10.8 mg, 55 µmol) was added, and the reaction mixture was stirred at room 
temperature for 1 h. Next, sodium cyanoborohydride (3.5 mg, 51 µmol) was added as a 
reducing agent to reduce the unstable hydrazone linkage (C=N-NH-), and then the mixture 
was stirred at room temperature for 24 h. Purification was performed with dialysis against a 
large quantity of water (2.0 L) using a pre-swollen semi-permeable membrane (MWCO: 
12,000–14,000) for 3 days. The dialysate water was exchanged at 2, 5, 8, 24 and 48 h after the 
beginning of dialysis. After purification, 3.0 mL of the solution was freeze-dried to determine 
the concentration and the degree of the functionality of the Tyr residue in the 1H-NMR 
spectra. The 1H-NMR spectra of the lyophilized NCL or CL micelles in DMSO-d at 80 ºC 
showed the aromatic protons of the Tyr residue, and the degree of functionality of the Tyr 
residue of the NCL and CL micelles was 45 % and 38 %, respectively, as determined from the 
peak intensity ratio of the aromatic protons in Tyr (δ 6.8 and 7.2 ppm) to the methine proton 
in the PLA segment (δ 5.2 ppm) of the block copolymer (see supporting information, Fig. 
S6). 
 
2.6. Radiolabeling of the Tyr-NCL and Tyr-CL micelles 
 
A solution of Na125I in 10 mM phosphate-buffered saline (PBS) (15 µL, 74 MBq/mL, 
PerkinElmer, Inc., USA) was added to a solution of Tyr-NCL or Tyr-CL micelles in 10 mM 
PBS (300 µL, 2.0 mg/mL). A solution of chloramine T in 10 mM PBS (100 µL, 2.0 mM) was 
added to the reaction mixture, which was incubated at room temperature for 10 min. Next, the 
reaction was quenched by the addition of a solution of sodium peroxodisulfate in 10 mM PBS 
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(100 µL, 40 mM). After shaking for a few minutes, the unreacted 125I and other chemicals 
were removed by passing the sample through a PD-10 column (GE Healthcare, USA) using 
PBS as an eluent prior to the biodistribution study. The radioactivity of each fraction was 
measured using a γ-counter (Aloka, Japan) (see supporting information, Fig. S7). 
 
2.7. Biodistribution of the 125I-labeled Tyr-NCL and 125I-labeled Tyr-CL micelles 
 
The biodistribution of the 125I-labeled Tyr-NCL and 125I-labeled Tyr-CL micelles was 
evaluated in tumor-bearing, 5-week-old-male BALB/c mice (n = 4, Charles River, Japan). 
Each tumor-bearing mouse was prepared with a subcutaneous injection of colon-26 cells (1.0 
x 106 cells/mouse) into its back. When the volume of the tumor reached 100 mm3, the 
125I-labeled Tyr-NCL micelles or 125I-labeled Tyr-CL micelles were administrated to the 
tumor-bearing mice by intravenous injection at a dose of 1.3 mg micelles per kg body weight. 
The blood, liver, spleen, kidney and tumor samples were collected, using sodium 
pentobarbital (40 mg/kg) as an anesthetic, at defined time periods after the micelle injection. 
The radioactivity and the weight of the collected samples were measured using a γ-counter 
and a balance, respectively. The total volume of blood in each mouse was estimated using the 
following equation[32]: 
Total blood volume (mL) = body weight (g) × 8.45/100 (mL/g) 
 
2.8. Biodistribution of the boron species in the NCL and CL micelles 
 
The biodistribution of the boron species of the NCL and CL micelles in tumor-bearing mice 
was evaluated using ICP-MS. The tumor-bearing mice were prepared with a subcutaneous 
injection of colon-26 cells (1.0 x 106 cells/mouse) into its back. When the volume of the 
    
 - 12 - 
tumor reached 100 mm3, the NCL or CL micelles were administered to the tumor-bearing 
mice by intravenous injection at a dose of 0.20 mg boron atoms per kg body weight. The 
blood, liver, spleen, kidney and tumor samples were collected, using sodium pentobarbital (40 
mg/kg) as an anesthetic, at 24 h after the injection. The excised tissues were weighed and 
digested with 2 mL of HNO3 (ultratrace analysis grade, Wako, Japan) at 90 ºC for 3 h, and 
then the dissolved samples were diluted with distilled water. After filtering through a 0.45 µm 
filter, the boron concentration was measured using ICP-MS. 
 
3. Results and Discussion 
 
3.1. Preparation and characterization of the NCL and CL micelles 
 
Consistent with previous literature,[21] acetal-PEG-b-PLA-MA was synthesized by the 
successive anionic ring-opening polymerization of EO using potassium 
3,3-diethoxy-1-propanolate as an initiator, followed by the addition of D,L-lactide. The 
resulting block copolymer with a reactive potassium alkoxide terminus was capped by adding 
an excess of methacrylic anhydride to introduce a polymerizable methacryloyl group at the 
PLA chain end (supporting information, Scheme S1). The molecular weights of the PEG and 
PLA segments in the acetal-PEG-b-PLA-MA were found to be 9,500 and 5,000, respectively, 
as determined with SEC and 1H-NMR analysis (supporting information, Fig. S1 and S2). 
These are in good agreement with the theoretical values (PEG; Mn = 9,500, PLA; Mn = 5,000) 
obtained based on the initial monomer/initiator ratio. The SEC analysis also revealed that the 
acetal-PEG-b-PLA-MA had a narrow molecular weight distribution (Mw/Mn = 1.12). The 
degree of functionality of the acetal and the methacryloyl groups was found to be 95 and 
99 %, respectively, as determined with 1H-NMR analysis. The VB-carborane was synthesized 
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according to the previous literature;[25] viz., lithiation of both methine protons (CH) of 
o-carborane was performed using 2.0 equiv. of BuLi in THF, followed by the addition of 2.0 
equiv. of 4-vinylbenzyl chloride (supporting information, Scheme S2). The VB-carborane 
was obtained in 21 % yield after purification with column chromatography. The 
VB-carborane showed fluorescence in methanol (λex: 339 nm, λem: 380 mm), indicating that 
VB-carborane can be used not only as a model compound for 10B-compounds but also as a 
fluorescent probe. 
To prepare the acetal-PEG-b-PLA-MA micelles, the dialysis method was employed in this 
study because this method is known to form micelles with a relatively narrow size distribution. 
Block copolymer was first dissolved in DMAc, which is a good solvent for both the PEG and 
the PLA segment and the solution was dialyzed against water for 24 h. The average diameter 
of the acetal-PEG-b-PLA-MA micelles was 45.8 nm with a narrow size distribution (µ2/Γ2 = 
0.135), as determined with DLS measurement. Encapsulation of VB-carborane in the 
acetal-PEG-b-PLA-MA micelles was performed with the conventional solvent evaporation 
method using chloroform. This is a typical method for encapsulating hydrophobic drugs into 
the hydrophobic core of polymeric micelles through the hydrophobic interactions.[27],[28] The 
average diameter of the VB-carborane-encapsulating acetal-PEG-b-PLA-MA micelles (NCL 
micelles) increased from 45.3 nm to 81.1 nm as shown in Fig. 2. This is probably due to the 
formation of a loosely associated PLA core as a result of the swelling of the hydrophobic PLA 
core upon the addition of chloroform.[24] To prepare the CL micelles, both VB-carborane and 
AIBN were encapsulated into acetal-PEG-b-PLA-MA micelles using the solvent evaporation 
method, and the polymerization of the core was conducted at 60 ºC for 24 h. The 
characteristics of the NCL and CL micelles are summarized in Table 1. The average diameter 
and size distribution (85.3 nm, µ2/Γ2 = 0.171) of the CL micelles were almost similar to those 
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of the NCL micelles (81.1 nm, µ2/Γ2 = 0.158), suggesting that the core polymerization process 
does not influence the average diameter or size distribution of the micelles. 
To confirm the encapsulation of VB-carborane into the CL micelles, column fractionation 
by gel filtration chromatography was conducted using PBS as the eluent, and the boron atom 
concentration and light scattering intensity of each collected fraction were measured using 
ICP-AES and DLS, respectively (Fig. 3). The boron atoms were detected in the 3 and 4 mL 
fractions, and a significant increase in the light scattering intensity was also observed in the 
same fractions due to the co-existence of boron atoms and micelles in the solution. These 
findings indicate that VB-carborane was obviously encapsulated into the CL micelles. The 
loading content of boron atoms in the NCL and CL micelles was determined to be 0.29 wt% 
(loading efficiency: 3.2 %) and 0.26 wt% (loading efficiency: 3.1 %), respectively, as 
summarized in Table 1. The loading content of boron atoms in the CL micelles was similar to 
that in the NCL micelles, strongly indicating that leakage of VB-carborane from the micelles 
did not occur at all during the polymerization process. 
To clarify whether the VB-carborane was covalently cross-linked in the core of the micelles, 
1H-NMR analysis of the lyophilized NCL and CL micelles was conducted in CDCl3, which is 
a good solvent for both acetal-PEG-b-PLA-MA and VB-carborane (Fig. 4). In the case of the 
NCL micelles, the protons attributed to the methacryloyl end group were clearly observed at 
5.6 and 6.2 ppm, and vinyl protons of VB-carborane were observed at 5.7 and 6.7 ppm. These 
findings indicate that both acetal-PEG-b-PLA-MA and VB-carborane were obviously 
dissolved in CDCl3. However, both the methacryloyl and the vinyl protons disappeared in the 
1H-NMR spectrum of the CL micelles, suggesting that the copolymerization (cross-linking) of 
the acetal-PEG-b-PLA-MA and VB-carborane proceeded with high conversion into the core 
of the micelles. 
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3.2. Leakage of VB-carborane from the NCL and CL micelles 
 
The leakage of the encapsulated 10B-compound from nano-sized carriers under 
physiological conditions in the presence of serum proteins is an important issue for in vivo 
application. The leakage of VB-carborane from the NCL and CL micelles was evaluated at 
0.2 mg of micelles per mL, well above the critical association concentration (ca. 2.0 µg/mL), 
under physiological conditions in the presence or absence of 10 % FBS, because the 
dissociation of the micelles occurs below the critical association concentration. The amount of 
VB-carborane remaining in the micelles was determined based on the fluorescence intensity 
of VB-carborane (λex: 339 nm, λem: 380 nm). Fig. 5 shows the time courses of the leakage of 
VB-carborane from the NCL and the CL micelles. Almost no leakage of VB-carborane was 
observed from either the NCL or the CL micelles in the absence of FBS (Fig. 5(a)), due to the 
sufficiently strong hydrophobic interaction between VB-carborane and the hydrophobic PLA 
core of the NCL micelles. In sharp contrast, significant amounts of VB-carborane were 
immediately leaked from the NCL micelles in the presence of FBS, and eventually only 20 % 
of the VB-carborane was still encapsulated in the NCL micelles after 48 h (Fig. 5(b)). There 
are several reports on the leakage of hydrophobic drugs from polymeric micelles in the 
presence of protein, due to the loss of micelle integrity caused by the interaction between 
some blood components (α- and β-globulin and/or BSA) and the micelles.[17],[29],[31] Notably, 
the CL micelles showed no leakage of VB-carborane even in the presence of FBS. The 
significantly reduced leakage of VB-carborane from the CL micelles results from the highly 
stable core-shell structure of these micelles and the absence of VB-carborane diffusion from 
the core to the solution is due to the existence of the cross-linking bonds between the 
VB-carborane and the PLA core. 
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3.3. Stability of the micelles against serum proteins 
 
To obtain further information on the stability of the NCL and CL micelles in the presence 
of serum proteins, SEC analyses of the NCL or CL micelles were performed at 0 h (micelle 
alone) and 24 h after co-incubation with 10 % FBS at 37 ºC. The SEC analyses were 
monitored by fluorescence (λex 339 nm, λem 380 nm) and RI detection. As shown in Fig. 6(a) 
and 6(b), the peaks attributed to the NCL and CL micelles were observed by both 
fluorescence and RI detection at 14 min in the region of the exclusion limit (Mn > 300,000) 
because the VB-carborane was encapsulated in the micelles. Additionally, the small peak at 
33 min (Mn = ca. 13,000) was observed only by the RI detection, due to the existence of a 
small amount (< 3 %) of free polymer.[21] Fig. 6(c) and 6(d) show the SEC chromatograms of 
the NCL and CL micelles at 24 h after co-incubation with 10 % FBS. In the case of the NCL 
micelles, two peaks were detected by both fluorescence and RI detection; viz., the peaks at 14 
and 27.5 min correspond to the micelles and the serum albumin, respectively (Fig. 6(c)). This 
clearly indicates that the leakage of VB-carborane from the NCL micelles occurred, 
presumably due to the loss of micelle integrity and/or diffusion of VB-carborane from the 
core to the solution. Consequently, the leaked VB-carborane interacted with serum albumin to 
form a VB-carborane/albumin complex, which was detected at 27.5 min with the fluorescence 
detection. Note that a 47 % decrease in the area of the NCL micelle peak at 14 min was 
observed, along with a 48 % increase in the area of the free polymer peak at 33 min with RI 
detection, suggesting a loss of micelle integrity caused by the interaction between the NCL 
micelles and serum albumin. On the contrary, the CL micelles showed no fluorescence peak 
at 27.5 min, attributable to serum albumin at 24 h, even after co-incubation with 10 % FBS 
(Fig. 6(d)); viz., no leakage of the VB-carborane from the CL micelles had occurred. It 
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should also be noted that almost no change in the area of either the CL micelle peak at 14 min 
or the free polymer peak at 33 min was observed with the RI detection, indicating that no loss 
of micelle integrity and no diffusion of VB-carborane from the core to the solution occurred, 
due to the existence of the covalent bonds between VB-carborane and the PLA core of the 
micelles. Thus, the CL micelles showed minimal interaction with the serum components due 
to its highly stable core-shell structure made possible by cross-linking bonds between the 
VB-carborane and the PLA core, which reduced the leakage of VB-carborane and prevented 
the loss of micelle integrity even in the presence of 10 % FBS. 
 
3.4. Biodistribution of the 125I-labeled of Tyr-NCL and 125I-labeled Tyr-CL micelles 
 
The cytotoxicity of the CL micelles is one of the important issues for the development of 
BNCT in vivo. The cytotoxicity of the NCL micelles, CL micelles, VB-carborane, BPA and 
BSH against colon-26 cells was evaluated in the presence of 10% FBS in the cell culture 
medium as shown in Figure S4. Note that the CL micelles and BSH showed no toxicity even 
at high concentration ([B] = 6.0 mM). In contrast, 50 % inhibitory concentration (IC50) values 
of the NCL micelles, VB-carborane, and BPA were 4.2 mM, 2.6 mM, and 4.7 mM, 
respectively. Although the cytotoxicity of the VB-carborane (IC50 = 2.6 mM) is slightly 
higher than that of the BPA (IC50 = 4.7 mM), the cytotoxicity of the NCL micelles (IC50 = 4.2 
mM) was similar to that of the clinically approved BPA (IC50 = 4.7 mM). Moreover, the 
cytotoxicity of the VB-carborane is lower than that of the nido-carborane derivative (IC50 = 
0.5 mM),[33] which has been used in the 10B-compound-conjugated liposomes[10]-[12]. These 
results indicate that the cytotoxicity of VB-carborane was negligible in BNCT. Notably, the 
cytotoxicity of the CL micelles (IC50 = not determined) was significantly lower than that of 
the NCL micelles (IC50 = 4.2 mM). These results indicate that the leakage of the 
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VB-carborane from the NCL micelles occurred in the presence of 10% FBS, leading to the 
cytotoxicity caused by the free VB-carborane. In sharp contrast, the leakage of VB-carborane 
from the CL micelles was suppressed even in the presence of 10% FBS because the 
VB-carborane was conjugated with the core of micelles through the covalent bonds. It can be 
concluded that the CL micelle system formulated by the polymerization of 
acetal-PEG-b-PLA-MA and newly synthesized VB-carborane is utilized for BNCT from the 
standpoint of the cytotoxicity. 
 To clarify the effect of cross-linkage on the biodistribution of the micelles, the preparation of 
125I (RI: radioisotope)-labeled NCL and CL micelles were performed by employing the acetal 
group at the PEG end. Thus, the acetal groups at the PEG end of the NCL and CL micelles 
were hydrolyzed using acid to obtain the reactive aldehyde groups (supporting information, 
Fig. S5), followed by the addition of L-tyrosine hydrazide (Tyr) and sodium 
cyanoborohydride as a reducing agent. In the 1H-NMR spectra of the NCL and CL micelles, 
the degree of Tyr functionality in the NCL and CL micelles was determined to be 45 and 
38 %, respectively, based on the integral ratio of the peaks between the aromatic protons of 
the tyrosine residues (6.98 and 7.30 ppm) and methine protons of the PLA segments (5.51 
ppm) (supporting information, Fig. S6). The characteristics of the Tyr-conjugated NCL 
(Tyr-NCL) and CL (Tyr-CL) micelles are also summarized in Table 1. Although the 
Tyr-NCL and Tyr-CL micelles bear the primary amino group and the hydrazone linkage 
around the PEG end (supporting information, Fig. S6), their average diameter and zeta 
potential were almost consistent with those of the NCL and CL micelles before the 
installation of the Tyr group. Thus, the effect of the Tyr groups on the biodistribution of the 
NCL and CL micelles is not considered. 125I-labeling was conducted using the conventional 
chloramine T method, followed by purification with gel chromatography (supporting 
information, Fig. S7). The radioactivity levels of the 125I-labeled Tyr-NCL and Tyr-CL 
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micelles in the blood, liver, spleen, kidney and tumor samples are expressed as a percentage 
of the injected dose per gram of tissue (%ID/g) at specified times after intravenous 
administration in tumor-bearing mice, as shown in Fig. 7. There were no differences in the 
distribution in the liver and spleen between the 125I-labeled Tyr-NCL and the Tyr-CL micelles 
(Fig. 7(b), 7(d)). In sharp contrast, the concentration of 125I-labeled Tyr-NCL micelles in the 
blood was approximately 30 %ID/g, even 10 min after administration, whereas almost all the 
125I-labeled Tyr-CL micelles (43 %ID/g) remained in the blood stream at the same time 
(Fig.7(a)). This suggests that a portion of the 125I-labeled Tyr-NCL micelles were 
immediately eliminated from the blood stream after injection because the 125I-labeled 
Tyr-NCL micelles showed a higher radioactivity level compared to the 125I-labeled Tyr-CL 
micelles in the kidney after 10 min (Fig.7(c)). Note that 7.8 %ID/g of 125I-labeled Tyr-CL 
micelles still remained in the blood stream after 24 h, whereas only 3.1 %ID/g of 125I-labeled 
Tyr-NCL micelles remained after 24 h (Fig. 7(a)). These results indicate that the Tyr-CL 
micelles were poorly eliminated from the blood stream through renal clearance due to the 
enhancement of the stability of the micelles against serum proteins and/or dilution in the 
blood stream caused by the introduction of cross-linking bonds between the VB-carborane 
and the PLA core. It should be noted that the 125I-labeled Tyr-CL micelles accumulated in 
higher amounts in the tumor tissue (2.9 %ID/g) compared with the 125I-labeled Tyr-NCL 
micelles (1.8 %ID/g) after 24 h (Fig. 7(e)), which is probably due to the facilitation of the 
EPR effect (passive targeting) of the 125I-labeled Tyr-CL micelles based on the prolonged 
blood circulation time caused by the enhanced stability of the CL micelles in the blood 
stream. 
 
3.5. Biodistribution of the boron species in the NCL and CL micelles 
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To clarify the biodistribution of the boron species (VB-carborane) of the CL and NCL 
micelles, the concentration of boron atoms in the blood, liver, spleen, kidney and tumor 
samples at 24 h after intravenous injection of the NCL micelles and the CL micelles was 
determined using ICP-MS. As shown in Fig. 8, the boron concentrations in both blood 
(13.5 %ID/g) and tumor (5.4 %ID/g) after injection of the CL micelles were higher than those 
after injection of the NCL micelles (blood: 1.8 %ID/g, tumor: 1.4 %ID/g). Fig. 9 shows the 
comparison of the biodistribution between 125I-labeled Tyr-micelles and the boron species that 
was determined based on radioactivity and using ICP-MS, respectively, at 24 h after injection 
of the CL micelles (Fig. 9(a)) and the NCL micelles (Fig. 9(b)). Almost no difference was 
seen in the concentration of the boron species in the CL micelles and the 125I-labeled Tyr-CL 
micelles, although low concentration of boron species was observed in the liver probably due 
to difficulty in complete dissolution of the large size of liver tissues with nitric acid (Fig. 
9(a)). This finding indicates that the biodistribution of the boron species in the CL micelles 
was similar to that of the 125I-labeled Tyr-CL micelles 24 h after injection in tumor-bearing 
mice. In the case of the NCL micelles (Fig.9(b)), however, the concentrations of the boron 
species in all organs and blood were lower than the concentrations of 125I-labeled Tyr-NCL 
micelles. To clarify the difference in the concentrations in blood and tumor between 
125I-labeled Tyr-micelles and the boron species, the ratio of the concentration (%ID/g) of the 
CL micelles to the NCL micelles (CL/NCL) in blood and tumor, as determined based on 
radioactivity and using ICP-MS, were summarized in Table 2. The CLICP/NCLICP ratio in 
blood (15.8) was significantly higher than the CLRI/NCLRI ratio in blood (2.5). This result 
obviously indicates that the VB-carborane was leaked from the NCL micelles readily into the 
blood stream, whereas the leakage of the VB-carborane from the CL micelles might be 
suppressed by the existence of the cross-linking bonds between the VB-carborane and the 
PLA core, leading to the high accumulation of the boron species in tumor (CLICP/NCLICP: 3.8, 
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CLRI/NCLRI: 1.6) through the EPR effect. Based on these results, it is concluded that the CL 
micelles can be used as a novel boron carrier in BNCT because the CL micelles can deliver 
both the polymer and the boron species into tumor tissues with high efficiency.  
 
4. Conclusion 
 
In conclusion, we have demonstrated the preparation of the CL micelles composed of 
acetal-PEG-b-PLA-MA and 1,2-bis(4-vinylbenzyl)-closo-carborane. Both the leakage of 
VB-carborane from the micelles and the loss of micelle integrity were suppressed even in the 
presence of FBS due to the introduction of cross-linking bonds between the VB-carborane 
and the PLA core. Additionally, the CL micelles achieved a prolonged blood circulation time 
and an enhanced accumulation in tumor tissues. Therefore, the CL micelles represent a 
promising approach to the creation of novel boron carrier for cancer BNCT, and further in 
vitro and in vivo BNCT studies and the improvement of the boron loading contents in the 
micelles are now being carried out in our laboratory. 
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Fig. 1. Schematic illustration of the preparation of NCL and CL micelles composed of 
acetal-PEG-b-PLA-MA and polymerizable carborane (VB-carborane). 
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Fig. 2. Size distributions of NCL micelles (closed squares) and CL micelles (open circles).  
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Fig. 3. Elution profiles of the CL micelles on a PD-10 (gel filtration) column. The 
concentration of boron atoms and the scattering intensity are indicated by the closed squares 
and open circles, respectively. 
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Fig. 4. 1H-NMR spectra of lyophilized NCL micelles (a) and CL micelles (b) in chloroform-d. 
 
solvent 
solvent 
    
 - 29 - 
0 10 20 30 40 50
0
20
40
60
80
100
 
 
En
ca
ps
ul
at
ed
 ca
rb
or
an
e i
n 
m
ice
lle
s [
%
]
Time [h]
(a)
     
0 10 20 30 40 50
0
20
40
60
80
100
120
 
 
En
ca
ps
ul
at
ed
 ca
rb
or
an
e i
n 
m
ice
lle
s [
%
]
Time [h]
(b)
* *
 
 
Fig. 5. Time-dependent leakage of VB-carborane from NCL micelles (closed square) and CL 
micelles (open circle) in the absence (a) or presence (b) of 10 % FBS at 37 ºC (n = 3, mean + 
SD). *P < 0.01 
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Fig. 6. SEC profiles for NCL micelles alone (a), CL micelles alone (b), NCL micelles with 
10 % FBS after 24 h incubation (c), and CL micelles with 10 % FBS after incubation (d) 
detected with a fluorescence detection (solid line) and a refractive index detection (dashed 
line). (Column, Superose TM 6 10/300 GL; flow rate, 0.5 mL/min; eluent, 10 mM phosphate 
buffer solution, pH 7.4; temperature, 40 °C) 
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Fig. 7. Tissue distribution profiles of 125I-labeled Tyr-CL micelles (open circles) and 
125I-labeled Tyr-NCL micelles (closed squares) in the blood (a), liver (b), kidney (c), spleen 
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(d), and tumor (e) after intravenous injection in tumor-bearing mice, determined based on 
radioactivity (n = 4, mean + SD). *P < 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 - 33 - 
Blood Liver Spleen Kidney Tumor
0
10
20
30
 
 
%
 in
je
ct
ed
 d
os
e /
 g
 ti
ss
ue
**
*
*
**
 
 
Fig. 8. Biodistribution of the boron species at 24 h after intravenous injection of CL micelles 
(black bars) and NCL micelles (white bars) in tumor-bearing mice, as determined by ICP-MS. 
(n = 4, mean + SD). *P < 0.05, **P < 0.01 
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Fig. 9 The comparison of the biodistribution between 125I-labeled Tyr-micelles (black bars) 
and boron species (white bars), determined based on radioactivity and using ICP-MS, 
respectively, at 24 h after injection of CL micelles (a) and NCL micelles (b) in tumor-bearing 
mice. (n = 4, mean + SD). *P < 0.05, **P < 0.01 
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Table 1. Characterization data of the micelles 
micelles Diameter (nm)a
Size distribution 
(µ2/Γ2)a
Zeta potential 
(mV)b
Loading content of 
boron atom (wt%)c 
Functionality of Tyr 
(mol%/polymer)d 
NCL 81.1 0.158 -0.33 + 0.31 0.29
CL 85.3 0.171 -0.69 + 0.33 0.26
Tyr-NCL 87.1 0.192 -0.96 + 0.39 0.29 45
Tyr-CL 88.9 0.183 -0.47 + 0.16 0.27 38
 
a Determined by DLS at 37 ºC and pH 7.4 in 10 mM phosphate buffer containing 150 mM 
sodium chloride. 
b Determined by electrophoretic light scattering at 37 ºC and pH 7.4 in 5 mM phosphate buffer 
(average + SD., n = 3). 
c Determined by ICP-AES using a calibration curve based on boric acid. 
d Determined by 1H-NMR analysis in DMSO-d at 80 ºC. 
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Table 2. The ratio of the concentration of the CL micelles to the NCL micelles (CL/NCL) in 
blood and tumor, as determined by radioactivity (RI) and ICP-MS (ICP). 
Blood Tumor
RI(CLRI/NCLRI)a 2.5 1.6
ICP(CLICP/NCLICP)a 15.8 3.8
 
a Calculated by the following equation: (%ID/g of CL micelles) / (%ID/g of NCL micelles). 
